STOCK PURCHASE AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023Stock Purchase Agreement • February 28th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of December 28, 2023 (the “Signing Date”), by and between Novartis Pharma AG (the “Investor”), a corporation organized and existing under the laws of Switzerland, with its principal business office at Lichtstrasse 35, CH-4056 Basel, Switzerland, and Voyager Therapeutics, Inc. (the “Company”), a Delaware corporation, with its principal place of business at 75 Hayden Avenue, Lexington, MA 02421.
INVESTOR AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023Investor Agreement • February 28th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is dated as of December 28, 2023 and effective as of the Closing (as defined below), by and between Novartis Pharma AG (the “Investor”), a corporation organized and existing under the laws of Switzerland, with its principal business office at Lichtstrasse 35, CH-4056 Basel, Switzerland, and Voyager Therapeutics, Inc. (the “Company”), a Delaware corporation, with its principal place of business at 75 Hayden Avenue, Lexington, MA 02421.
AMENDMENT NO. 3 TO CONSULTING AGREEMENTConsulting Agreement • February 28th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Consulting Agreement (this ”Amendment”) effective as of May 1, 2023 (“Amendment Effective Date”) is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office located at 64 Sidney Street, Cambridge, MA 02139 (“Voyager”) and (ii) Dinah Sah, Ph.D., an individual residing at 15 Huckleberry Road, Hopkinton, MA 01748 (“Consultant”).
AMENDMENT NO. 2 CONSULTING AGREEMENTConsulting Agreement • February 28th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances)
Amendment No. 2 (this “Amendment”) to the Consulting Agreement, between Dinah Sah (“Consultant”) and Voyager Therapeutics, Inc. (“Voyager”) effective as of June 28, 2019 (the “Effective Date”) as amended by Amendment No. 1 to the Consulting Agreement, effective as of September 16, 2019 (together, the “Agreement”), is entered into as of June 27, 2022 (the “Amendment Effective Date”). Capitalized terms used in this Amendment and not otherwise defined shall have the meanings given such terms in the Agreement.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AND...License and Collaboration Agreement • February 28th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into and made effective as of December 28, 2023 (the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Hayden Ave, Lexington, MA 02421 (“Voyager”), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, having an address at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Voyager and Novartis are referred to herein individually as a “Party” and collectively as the “Parties”.
